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Recent epigenome-wide association studies have
indicated a potential role for epigenetic variation in
the etiology of complex human diseases. However,
one major challenge is to distinguish true epigenetic
variation from changes caused by differences in cellular
composition between the disease and non-disease
state, a problem that is particularly relevant when
analyzing whole blood. For studies with large numbers
of samples, it can be expensive and very time consuming
to perform cell sorting, and it is often not clear which is
the correct cell type to profile. Two recently published
papers have attempted to address this confounding issue
using bioinformatics.differences in cellular composition between the diseaseCell-type composition as a confounding factor in
epigenome-wide association studies
Despite the success of genome-wide association studies
(GWASs) in identifying common disease-associated loci
in humans, a substantial proportion of disease causality
remains unexplained. Consequently, there is now strong
interest in exploring the role of inter-individual epigen-
etic variation in disease pathogenesis. Epigenome-wide
association studies (EWASs) have been initiated by many
different groups to systematically catalogue epigenetic
variation (with an emphasis on DNA methylation) in
various diseases. These EWASs have the potential to
yield important new insights into disease pathogenesis
and to provide biomarkers, but conducting such studies
presents challenges not encountered in GWASs [1]. The
main challenge is that whereas germline genetic vari-
ation is present and unaltered in virtually every cell of a
given individual, epigenetic profiles are subject to tem-
poral, spatial and developmental dynamics, and are in-
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or a few cell types may have an etiological role in the
disease. Often cells from the target tissue are not easily
available in large enough numbers to provide adequate
statistical power, and thus surrogate tissues, most com-
monly whole blood, are used instead. The expectation is
that the surrogate tissue will reflect epigenomic pertur-
bations found in the target tissue, or at least yield bio-
markers that - although not directly causative of the
disease - can still be used for predictive, diagnostic or
prognostic purposes.
Regardless of whether target or surrogate tissues are
used, a major issue for both designing and correctly
interpreting an EWAS is to determine whether disease-
associated variation is truly epigenetic, or is the result of
and non-disease state. For example, during aging the cel-
lular composition of blood is often altered [2], and thus
the measured epigenetic variation may be due to differ-
ences in tissue-specific profiles between different blood
subsets. The ideal solution to this problem is to isolate
and profile individual cell subsets. In many cases this is
not practicable on a large scale and consequently there
is a reliance on unsorted tissues. Two recent papers - by
Zou et al. [3] and Jaffe and Irizarry [4] - highlight this
issue, and propose a post hoc bioinformatics solution to
correct for confounding cell-type bias in EWASs.Accounting for cellular heterogeneity is critical in
epigenome-wide association studies
Writing in Genome Biology, Jaffe and Irizarry [4] present
a method for accounting for cellular heterogeneity in
whole blood using an existing reference database of
sorted blood cells (granulocytes, CD8+ and CD4+ T cells,
CD56+ natural killer cells, CD19+ B cells and CD14+
monocytes) from six adult male samples. They found
that a striking 63.5% of CpG sites showed differences in
methylation across the cell types, and provide a statis-
tical summary of cell-type variability as an additional file.ntral Ltd. The licensee has exclusive rights to distribute this article, in any
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[5], which uses a random effects model at each of the
CpGs, but they have adjusted it somewhat for genetics
by removing probes containing an annotated single nu-
cleotide polymorphism (SNP) at the CpG site of interest.
The algorithm used is now freely available in the popular
minfi Bioconductor package [6], which will allow re-
searchers to incorporate it into existing pipelines.
Epigenome-wide association studies without the
need for cell-type composition
Zou et al. [3] report a non-reference-based method for
correcting cell-type composition that differs between
cases and controls. This approach has a benefit over that
of Jaffe and Irizarry in that it can be applied to any tissue
type rather than just blood. The method is an adjust-
ment of an existing algorithm called FaST-LMM, which
has previously been used in a GWAS [7] and performs a
linear mixed model analysis. Unfortunately, use of the
technique is restricted to specific case versus control
studies. This means it is not possible to perform regres-
sion analysis or analysis with multiple conditions, and it
also restricts the power of the method in twin design
studies, as there is no opportunity to perform pair-wise
analysis. Liu et al. [8] recently reported an EWAS for
rheumatoid arthritis in which they corrected for cellular
heterogeneity using a reference-based approach; in their
paper, Zou et al. showed that both methods produce
consistent results. They also applied their approach to
breast cancer data from The Cancer Genome Atlas
(TCGA) and produced results that showed enrichment
for known genes and pathways. One concern regarding
the method is that its power relies on a small number of
loci being true associations (see Supplementary Figure 8
of [3]); that is to say, the number of differences due to
the phenotype of interest is small (<1% of sites tested).
This is a potential concern when investigating cancer
datasets, for example, in which a large number of
changes occur.
Problems with correcting for cellular
heterogeneity
The importance of these new methods is that they may
overcome the problem of spurious correlations related
to differences in cell populations. The finding by Jaffe
and Irizarry that up to 63.5% of CpGs show significant
differences in methylation in blood cell populations
would mean that some variation in the phenotype of
interest may occur at these sites by chance. Indeed, they
applied their method to measure cell composition in
peripheral blood taken from a number of studies that
looked into age-related methylation differences (aDMPs).
They found that 86.7% of aDMPs varied significantly
(P value <0.05) across cell type. It has been reported [9],however, that a reasonable proportion of these aDMPs are
shared among tissues and hence it would be unlikely that
the cause of these differences in blood is the difference in
cell-type composition, despite being labelled as such. It is
also possible that some, or even many, disease-specific
epigenetic changes occur at tissue-specific sites [10].
Therefore, although these methods provide useful insights
they do not provide a holy grail for analysis, and any
findings from EWASs must be considered very carefully.
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